Healionics is a clinical-stage company addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure. Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of infection and occlusion suffered by current devices. We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices: scarring and infection. The company is currently conducting human studies of STARgraft and has 33 patents issued or pending.
Location: United States, Washington, Seattle
Total raised: $15.95M
Founded date: 2007
Investors 15
Show more
Funding Rounds 4
| Date | Series | Amount | Investors |
| 10.05.2024 | Grant | $1.25M | - |
| 22.02.2024 | Series A | $5.5M | - |
| 13.05.2021 | - | $4.7M | - |
| 24.09.2019 | - | $4.5M | - |
Mentions in press and media 15
| Date | Title | Description |
| 02.04.2025 | Healionics Granted US Patent for STARgraft Technology | STARgraft vascular graft SEATTLE, WA, UNITED STATES, April 2, 2025 /EINPresswire.com/ -- Healionics Corporation, a developer of synthetic biomaterial-based medical devices, today announced that the U.S. Patent and Trademark Office has issue... |
| 07.08.2024 | Healionics announces 12-month clinical results for STARgraft | STARgraft vascular graft SEATTLE, WA, USA, August 7, 2024 /EINPresswire.com/ -- Healionics Corporation, a developer of synthetic biomaterial-based medical devices, today announced 12-month clinical results in the ongoing human trial of its ... |
| 26.06.2024 | Envisioning a future where food is synonymous with health, fostering longevity, productivity, and societal well-being | If you missed Carter’s testimony at the Senate hearing, “Feeding a Healthier America: Current Efforts and Potential Opportunities for Food is Medicine,” the replay is available here. The hearing emphasized the importance of nutrition to red... |
| 23.05.2024 | Clinical results for Healionics’ STARgraft featured at VASA conference | STARgraft vascular graft SEATTLE, WA, USA, May 23, 2024 /EINPresswire.com/ -- Healionics Corporation, a developer of biomaterial-based medical devices, today announced positive clinical results in an ongoing human study of its STARgraft vas... |
| 10.05.2024 | Healionics Awarded $1.25M NIH Grant to Support Commercialization of STARgraft Vascular Graft | STARgraft vascular graft SEATTLE, WASHINGTON, USA, May 9, 2024 /EINPresswire.com/ -- Healionics Corporation, a developer of biomaterial-based medical devices, today announced it has been awarded a $1.25 million Small Business Innovation Res... |
| 22.02.2024 | Healionics Closes $5.5 Million Series A-3 Financing Round | STARgraft vascular graft SEATTLE, WA, USA, February 22, 2024 /EINPresswire.com/ -- Healionics Corporation, a developer of biomaterial-based medical devices, today announced the close of a $5.5 million equity financing round led by Keiretsu ... |
| 31.05.2022 | Tech Coast Angels’ Portfolio Company Healionics Honored with Angel Capital Association’s 2022 Luis Villalobos Award for Life Sciences | “We are thrilled that ACA has once again recognized a TCA portfolio company for its highest honor. It’s an ongoing tribute to Luis Villalobos, who believed in new ideas that could make a powerful impact,” said Jeff Lapin, TCA chairman. IRVI... |
| 13.05.2021 | Healionics Closes $4.7M Equity Financing | Healionics Corporation, a Seattle, WA-based private medical device company, closed a $4.7M equity financing. The round was led by Keiretsu Capital. The company also announced the conversion to equity of $5.2M in previously outstanding notes... |
| 13.05.2021 | Healionics raises $4.7M equity round to support commercialization of STARgraft vascular graft | |
| 13.05.2021 | Healionics raises $4.7M to commercialize artificial blood vessel tech | Healionics’ STARgraft vascular graft acts as an artificial blood vessel for dialysis patients. (Healionics Photo) New funding: Seattle-based medical technology company Healionics raised a $4.7 million round led by Keiretsu Capital to help c... |
Show more